Restricted accessResearch articleFirst published online 2025
Identification of DCTN1::ALK Fusion Leads to Initiation of ALK Inhibitor Therapy With Therapeutic Response in a Clinically Challenging Widely Metastatic Malignant Spindle Cell Neoplasm
SodaMChoiYLEnomotoM, et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
2.
AACR Project GENIE. Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7:818-831.
3.
CameronLBHitchenNChandranE, et al.Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 2022;1:Cd013453.
4.
CamidgeDRDziadziuszkoRPetersS, et al.Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the Global Phase III ALEX Study. J Thorac Oncol 2019. 14:1233-1243.
5.
VidrineDWBerryJFGarbuzovAFalconCTubbsRSBuiCJ. DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS. Childs Nerv Syst. 2021;37:2147-2151.
6.
DermawanJKDiNapoliSEMullaneyKA, et al.ALK-rearranged mesenchymal neoplasms: a report of 9 cases further expanding the clinicopathologic spectrum of emerging kinase fusion positive group of tumors. Genes Chromosomes Cancer. 2023;62:75-84.
7.
GaoFGaoFWuHLuJXuYZhaoY. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements. Thorac Cancer. 2022;13:1088-1090.
8.
KempsPGPicarsicJDurhamBH, et al.ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood. 2022;139(2):256-280. Blood 2023, 141:2785-2786.
